Threshold, Merck KGaA deal

Threshold received a $20 million milestone payment from Merck under a February deal to co-develop and commercialize TH-302. The payment was triggered by data from a Phase IIb trial to treat advanced pancreatic cancer showing that TH-302 plus gemcitabine met the primary endpoint of median progression-free survival (PFS) vs. gemcitabine alone. Overall survival (OS) data are expected next half. Threshold said the partners plan to discuss next steps for the compound in the indication (see BioCentury, Feb 6 & Feb. 27). ...